Sunday 10 January 2027 · 3–8 pm · San Francisco · JPM week

Where Pharma
Meets AI

An afternoon conference that brings together innovators in Artificial Intelligence and Pharma.

Get your ticket · $499 early bird See the agenda
Date
Sun 10 Jan 2027
Doors
15:00 · first panel 15:30
Venue
Homeland Loft, SoMa
Format
Four panels, four round tables

Proudly Sponsored By

Become a Sponsor →

Agenda

Four panels. Four round tables. One track.

Every panel runs thirty minutes, then the room breaks for thirty minutes of networking and round tables on the question the panel just argued. Chatham House rule on the discussion.

  1. 15:00

    Doors, coffee, badges

  2. 15:3030 min
    Panel 1

    Competitive Intelligence, Asset Scouting and Due Diligence with AI

    The three jobs that feed a licensing decision, taken as one workflow. Monitoring is now close to free, so the constraint has moved to interpretation — and deep-research agents hallucinate roughly twice the share of sources that shallower tools do. Scouting is a recall problem, not a writing problem, and every benchmark in this market was built by the company it flatters. Then the decision itself: sixty-two per cent of senior dealmakers say human-only decision-making is no longer defensible, twenty-two per cent would let a machine make the call, and they are the same people. Where does the line sit, and whose signature is on the file?

    • Monitoring is free
    • Recall over prose
    • A test a vendor can fail
    • Whose signature
  3. 16:00

    Networking and round tables · 30 min

  4. 16:3030 min
    Panel 2

    Using Agents to Launch Drugs

    The newest use case and the least proven: launch landscapes by market, brand strategy, country plans, competitor tracking through the launch window. It is also the one with live regulatory exposure — EU transparency obligations have been in force since August 2026, and nobody has tested whether an AI-assisted launch plan or competitor deck trips them.

    • Launch landscapes by market
    • EU transparency rules
    • Country plans at scale
  5. 17:00

    Networking and round tables · 30 min

  6. 17:3030 min
    Panel 3

    What does AI transformation mean for Pharma?

    Seventy-eight per cent of biopharma executives expect AI to change their business; nine per cent report significant returns. Both numbers come from the same survey, and every vendor reads them as early innings while every CFO reads them as three years with nothing to show. This panel is for the people who own that gap: what has actually changed in how a pharma company is run, which functions have been transformed rather than merely tooled, what the operating model looks like when agents write the first draft of everything, and which budget it all comes out of.

    • 78% expect, 9% see returns
    • Tooled or transformed
    • Whose budget
  7. 18:00

    Networking and round tables · 30 min

  8. 18:3030 min
    Panel 4

    Partnering with Big Tech: how to approach Anthropic, OpenAI and the labs

    The frontier labs now sell directly into life sciences with purpose-built models and dedicated teams, which changes what a pharma company can ask for — and what it has to bring. What a partnership with a lab actually looks like beyond a licence: co-development, early access, compute credits, custom models. Who to call and in what order. What the labs want from pharma that pharma undervalues. And the terms that matter: data residency, training rights, exclusivity, and what happens when the model you built on is retired.

    • Who to call
    • What the labs want
    • Data, credits, exclusivity
  9. 19:00

    Reception · until 20:00

Speakers

On stage.

Venue

Homeland Loft, SoMa.

A skylit loft on 11th Street in SoMa, eight blocks from the Westin St. Francis. A built-in stage, a ninety-nine-inch screen, and one long table for the evening reception.

221 11th Street
San Francisco, CA 94103

Open in Google Maps →

Why this room

The AI conference and the licensing conversation happen in different buildings.

The large pharma AI events programme tracks of R&D informatics and a commercial stream about field force and omnichannel. When a head of BD evaluations and a search-and-evaluation lead sat on a partnering panel this September, AI did not come up once.

Meanwhile the wider industry has stopped selling what models can do and started selling what has to be true before anyone trusts one: the evaluations, the verifiers, the permissions, the budget. That argument has not reached the people who sign deals.

This is that room.

Tickets

Early bird until 1 December.

One ticket covers the afternoon: all four panels, the round tables and the evening reception. Seats are limited by the room.

Attending from a pharma company? The ticket value is stated on every invoice so you can clear it with your compliance team.

Join us on Sunday 10 January.

Tell us who you are and we will come back with your ticket, or a conversation about speaking or sponsoring.

Get your ticket Talk to us about sponsoring